Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Nov 3, 2016

(R) Studies using Cantargia's antibodies in models of chronic myeloid leukaemia presented at the American Society of Hematology

Oct 24, 2016

(R) Cantargia raises MSEK 24.6 through exercise of warrants

Oct 20, 2016

(R) Cantargia to present new data from preclinical studies with CAN04 in non-small cell lung cancer

Sep 20, 2016

(R) Cantargia prepares intensified development strategy and capital raising

Sep 16, 2016

(R) Cantargia receives patent approval from the USPTO for IL1RAP in acute lymphoblastic leukemia

Sep 13, 2016

(R) Results from use of Cantargia’s antibodies against IL1RAP published in scientific journal Blood

Aug 24, 2016

(R) Cantargia interim report January – June 2016

Aug 22, 2016

(R) Cantargia raises kSEK 250 through exercise of warrants

Jul 15, 2016

(R) Cantargia obtains a granted patent from USPTO concerning IL1RAP in solid tumors

Jun 10, 2016

(R) Cantargia’s CAN04 product candidate show very good safety at high dose levels, paving the way for final GLP toxicity study in autumn 2016

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye